Anti-interleukin-17A antibody, pharmaceutical composition thereof and use thereof
The present invention relates to the fields of treating autoimmune diseases and molecular immunology, and specifically, to an anti-IL-17A antibody, a pharmaceutical composition thereof, and use thereof. The present invention relates to a monoclonal antibody or an antigen binding fragment thereof, wherein a heavy chain variable region of the monoclonal antibody comprises: HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 31-33 respectively, or HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NOs: 37-39 respectively, and a light chain variable region of the monoclonal antibody comprises: LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NOs: 34-36 respectively, or LCDR1-LCDR3 with amino acid sequences set forth in SEQ ID NOs: 40-42 respectively. Monoclonal antibodies of the present invention can specifically antagonize the binding of IL-17A to a ligand and inhibit activation of fibroblasts by IL-17A.
1 . An anti-interleukin-17A (anti-IL-17A) monoclonal antibody or an antigen-binding fragment thereof comprising:
a) a heavy chain variable region (VH) comprising three complementarity determining regions (HCDRs):
HCDR1 having the amino acid sequence set forth in SEQ ID NO: 31,
HCDR2 having the amino acid sequence set forth in SEQ ID NO: 32, and
HCDR3 having the amino acid sequence set forth in SEQ ID NO: 33; and
b) a light chain variable region (VL) comprising three CDRs (LCDRs):
LCDR1 having the amino acid sequence set forth in SEQ ID NO: 34,
LCDR2 having the amino acid sequence set forth in SEQ ID NO: 35, and
LCDR3 having the amino acid sequence set forth in SEQ ID NO: 36.
2 . The anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein
the VH comprises the amino acid sequence set forth in SEQ ID NO: 2, and
the VL comprises the amino acid sequence set forth in SEQ ID NO: 4.
3 . The monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein
the VH comprises the amino acid sequence set forth in SEQ ID NO: 6, and
the VL comprises the amino acid sequence set forth in SEQ ID NO: 8.
4 . The monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein
the VH comprises the amino acid sequence set forth in SEQ ID NO: 10, and
the VL comprises the amino acid sequence set forth in SEQ ID NO: 12.
5 . The monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein
the VH comprises the amino acid sequence set forth in SEQ ID NO: 14, and
the VL comprises the amino acid sequence set forth in SEQ ID NO: 12.
6 . The anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-IL-17A monoclonal antibody or antigen-binding fragment thereof is selected from an Fab, an Fab′, an F(ab′)2, an Fv, a single chain antibody, a humanized antibody, a chimeric antibody, and a diabody.
7 . The anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-IL-17A monoclonal antibody or antigen-binding fragment thereof comprises non-CDR regions derived from a species other than a mouse.
8 . A conjugate comprising the anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 and a conjugated portion comprising a detectable label.
9 . A reagent kit comprising the anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 .
10 . A pharmaceutical composition comprising the anti-IL-17A monoclonal antibody or antigen-binding fragment thereof of claim 1 and at least one pharmaceutically acceptable carrier.